Name
ABCM
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for ABCM
Name
Alternate Names
Ametycine
Mito-Medac
Mitocin
Mitocin-C
MitoExtra
Mitomycin-C
Mitomycin-X
Mutamycin
Mutamycine
Abbreviations
MITC
Mito
MITO-C
MMC
MTC
Category
Chemotherapy
Subcategory
Alkylating agent
Antibiotic
NSC Number
26980
026980
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin
Abbreviations
ADM
ADR
ADRI
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
123127
Primary Site
Histology
None
Remarks
Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic
Coding
This drug should be coded
Name
Alternate Names
Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719
Abbreviations
CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
026271
26271
Primary Site
Histology
None
Remarks
An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent
Coding
This drug should be coded
Name
Alternate Names
Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo
Abbreviations
BLE
BLEO
BLM
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
125066
Primary Site
Histology
None
Remarks
FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.
Coding
This drug should be coded